Navigating the Patient Journey Through Heart Failure Diagnosis

EP: 1.Identifying Key Risk Factors for Heart Failure

EP: 2.Socioeconomic Factors Impacting Development of Cardiac Disease

EP: 3.Distinguishing Between Heart Failure Classifications

EP: 4.Staging Heart Failure and the Importance of Early Diagnosis

EP: 5.The Role of the Primary Care Physician in Heart Failure Management

EP: 6.Four Pillars of Heart Failure Therapy

EP: 7.Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure

EP: 8.Key Takeaways From Heart Failure Clinical Trials

Now Viewing

EP: 9.Navigating the Patient Journey Through Heart Failure Diagnosis

EP: 10.Strategies for Treating Preserved Ejection Fraction (HFpEF)

EP: 11.Treatment Optimization Challenges Associated With Heart Failure

EP: 12.Financial Barriers Impeding Optimal Heart Failure Treatment

EP: 13.Trajectory of Heart Failure Treatment Strategies

EP: 14.Key Takeaways from Experts in Heart Failure Management

This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses strategies for converting stable heart failure patients from angiotensin-converting enzyme (ACE) inhibitors to angiotensin receptor-neprilysin inhibitor (ARNI) therapy. Albert emphasizes shared decision-making, explaining the benefits of switching, trying the new therapy, and reassessing how the patient feels. Once aware of improvements, patients are motivated to continue. Albert notes explaining therapeutic mechanisms helps, as ARNIs can actually reduce heart size versus just preventing enlargement with ACE inhibitors. Another of the 4 pillars of heart failure (HF) therapy, sodium-glucose cotransporter-2 (SGLT2) inhibitors, emerged unexpectedly from diabetes trials, reducing cardiovascular deaths across ejection fraction ranges. The ability to use SGLT2 inhibitors across HF spectrums makes adoption easier. For primary prevention, high-risk diabetes patients should receive SGLT2 inhibitors. In summary, SGLT2 inhibitors have rapidly become a core HF therapy thanks to unexpected cardiovascular benefits seen in diabetes trials. Their broad applicability creates substantial opportunities to improve outcomes across HF populations.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.